Additionally, we found that the combination of trastuzumab and U3 might not have an additive inhibition in receptor dimerization of HER-2 positive breast cancer cells, and may have competitive action in HRG-induced receptor dimerization, raising concerns regarding the ongoing clinical testing of this combination (NCT01512199). This evidence concerns the gene ERBB2 and breast carcinoma.